227 related articles for article (PubMed ID: 19117238)
1. Better results with the new generation bare metal stents.
Vik-Mo H
Scand Cardiovasc J; 2009 Apr; 43(2):84-6. PubMed ID: 19117238
[No Abstract] [Full Text] [Related]
2. Restenosis in coronary bare metal stents. Importance of time to follow-up: a comparison of coronary angiograms 6 months and 4 years after implantation.
Jørgensen E; Helqvist S; Kløvgaard L; Kastrup J; Clemmensen P; Holmvang L; Engstrøm T; Saunamaki K; Kelbaek H
Scand Cardiovasc J; 2009 Apr; 43(2):87-93. PubMed ID: 19031301
[TBL] [Abstract][Full Text] [Related]
3. A critical appraisal of the Janus carbostent.
Kornowski R
Catheter Cardiovasc Interv; 2009 Feb; 73(2):249-50. PubMed ID: 19156897
[No Abstract] [Full Text] [Related]
4. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
Vlaar PJ; Zijlstra F
JACC Cardiovasc Interv; 2009 Aug; 2(8):776-8. PubMed ID: 19695547
[No Abstract] [Full Text] [Related]
5. Gender medicine and drug eluting coronary stents.
Kornowski R
Catheter Cardiovasc Interv; 2010 Nov; 76(6):814-6. PubMed ID: 21104730
[No Abstract] [Full Text] [Related]
6. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
[TBL] [Abstract][Full Text] [Related]
7. A generation 2.5 drug-eluting stent?
Ellis SG
JACC Cardiovasc Interv; 2009 Oct; 2(10):986-8. PubMed ID: 19850259
[No Abstract] [Full Text] [Related]
8. Bare metal stent thrombosis 13 years after implantation.
Sarkees ML; Bavry AA; Galla JM; Bhatt DL
Cardiovasc Revasc Med; 2009; 10(1):58-9. PubMed ID: 19159857
[TBL] [Abstract][Full Text] [Related]
9. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
[TBL] [Abstract][Full Text] [Related]
10. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
11. DES in CTO: cosmetic or clinical benefit.
Goyal BK
Catheter Cardiovasc Interv; 2009 May; 73(6):780. PubMed ID: 19370758
[No Abstract] [Full Text] [Related]
12. Long-term complication after LM bifurcation treatment.
Wainstein MV; Ribeiro JP
Catheter Cardiovasc Interv; 2010 Jun; 75(7):1045-9. PubMed ID: 20146313
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions.
Uchida T; Popma J; Stone GW; Ellis SG; Turco MA; Ormiston JA; Muramatsu T; Nakamura M; Nanto S; Yokoi H; Baim DS
JACC Cardiovasc Interv; 2010 Apr; 3(4):403-11. PubMed ID: 20398868
[TBL] [Abstract][Full Text] [Related]
14. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results.
Ormiston JA; Webster MW; Schwartz RS; Gladding P; Stewart JT; Kay IP; Ruygrok PN; Hatrick R
JACC Cardiovasc Interv; 2009 Oct; 2(10):1017-24. PubMed ID: 19850264
[TBL] [Abstract][Full Text] [Related]
15. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents.
De Labriolle A; Bonello L; Lemesle G; Steinberg DH; Roy P; Xue Z; Kaneshige K; Suddath WO; Satler LF; Kent KM; Pichard AD; Lindsay J; Waksman R
Arch Cardiovasc Dis; 2009 Mar; 102(3):209-17. PubMed ID: 19375675
[TBL] [Abstract][Full Text] [Related]
17. Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry.
Tamburino C; Di Salvo ME; Capodanno D; Capranzano P; Parisi R; Mirabella F; Scardaci F; Ussia G; Galassi AR; Fiscella D; Mehran R; Dangas G
Catheter Cardiovasc Interv; 2009 Feb; 73(2):243-8. PubMed ID: 19156896
[TBL] [Abstract][Full Text] [Related]
18. Unprotected left main intervention: the light at the end of the tunnel?
Stone GW; Mintz GS
Circ Cardiovasc Interv; 2009 Jun; 2(3):156-8. PubMed ID: 20031711
[No Abstract] [Full Text] [Related]
19. Stent strut fracture: seeing is believing.
Carter AJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):619-20. PubMed ID: 18360854
[No Abstract] [Full Text] [Related]
20. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
